ADVANZ PHARMA enters into agreement to acquire the rights to Eisai’s Zonegran® in the EU, Middle East, Russia and Australia 14.06.21 LONDON, UK, June 14, 2021: ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced that it has entered into an agreement with Eisai Co., Ltd (Tokyo, “Eisai”) to acquire its European, Middle Eastern, Russian and Australian rights for the antiepileptic agent Zonegran® (zonisamide). Under the agreement, Eisai will continue to act as the distributor in Russia, through its local affiliate Limited Liability Company Eisai, and in Australia through its local affiliate Eisai Australia Pty Ltd., for an agreed transition period. In addition, Eisai and ADVANZ PHARMA have agreed to enter into a supply agreement under which Eisai’s UK affiliate, Eisai Manufacturing Limited, will serve as ADVANZ’s supplier of zonisamide for the transferred territory for an agreed transition period. Eisai will retain its rights to the product in Canada, Mexico and Asia and continue to distribute the product in certain licensed Asian countries. Guy Clark, Chief Corporate Development Officer at ADVANZ PHARMA said: “This deal is exactly in keeping with our strategic growth plans to grow our business both organically and inorganically. As highly experienced teams with significant commercial knowledge and global distribution networks in almost 100 countries, we are well positioned to integrate and distribute products quickly, helping to broaden prescriber choice and enhance access to critical medicines.” -Ends- About ADVANZ PHARMA ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe. With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe's major markets, the Company supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes. ADVANZ PHARMA has expertise in the anti-Infectives and endocrinology therapy areas, along with strong relationships with hospital decision makers, making it an attractive partner when commercialising complex medicines in Europe. ADVANZ PHARMA has an operational headquarters in London, an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe, and Australia, and an established global network of commercial partners throughout the rest of the world. For further information about ADVANZ PHARMA, visit www.advanzpharma.com. Contact details For media enquiries, please contact: Meral Nugent ADVANZ PHARMA Corp. Limited Tel: +44 208 588 9086 Mobile: +44 7557 49 60 35 meral.nugent@advanzpharma.com Press Releases — ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of g... 18 Nov 2021 Press Releases — ADVANZ PHARMA announces launch of MYRELEZ® in Norway, the first generic lanreotide for the... 11 Nov 2021 ADVANZ PHARMA announces launch of MYTOLAC® in Germany, the first generic lanreotide for th... 26 Jul 2021 About Responsibility Partnering News Careers Contact Ethics & Transparency Modern Slavery Statement Product Risk Materials Terms & Conditions Privacy Policy Recruitment Scams Follow us on LinkedIn Copyright 2021 ADVANZ PHARMA®. All Rights Reserved